wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 351 - 373 of 373.

Medicine/Pharmacology
05.06.2017
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist ‚? (trametinib) in combination with Opdivo ‚? (nivolumab) and Opdivo + Yervoy ‚? (ipilimumab) ‚? Collaboration expands upon existing clinical investigation of Op
Medicine/Pharmacology - Life Sciences
04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o
Medicine/Pharmacology - Life Sciences
03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a
Media - Administration/Government
02.06.2017
Medicine/Pharmacology - Life Sciences
02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent
Business/Economics - Environment/Sustainable Development
02.06.2017
Emissions trading scheme: acquisition of aviation data in 2018
Bern, 02.06.2017 - The integration of greenhouse gas emissions from the aviation sector into the emissions trading scheme (ETS) is a necessary step in order to link the Swiss and European schemes.
Medicine/Pharmacology - Life Sciences
02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.
Environment/Sustainable Development
01.06.2017
Research on road construction
Research on road construction
This year, Empa plays host to the biennial conference of the European Asphalt Technology Association (EATA).
Life Sciences
01.06.2017
New research tools
New research tools
At the age of 29, biotechnologist Randall Platt has already achieved a lot: more than 1,000 research laboratories around the world use a method that he developed.
Environment/Sustainable Development - Earth Sciences
01.06.2017
Landscapes remain under pressure
Bern, 01.06.2017 - Landscapes play an important role in Switzerland's quality of life and attractiveness as a location. They remain under considerable pressure: the latest results of the Landscape Monitoring Switzerland programme reveal a continuous deterioration in the quality of the country's landscapes.
Medicine/Pharmacology
31.05.2017
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process counters slow progress in developing new cryptosporidiosis treatments Scientists report discovery of Cryptosporidium PI(4)K inhibitor candidate KDU731 in new issue of Nature - Infectious disease scientists from Novartis, the University of Georgia and Washing
Civil Engineering/Traffic Engineering - History/Archeology
31.05.2017
The man with cities on his mind
The man with cities on his mind
Vittorio Magnago Lampugnani hasn't just written definitive reference works on urban planning and shaped a generation of ETH architects; he has also run numerous projects of his own.
Medicine/Pharmacology - Business/Economics
31.05.2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Building depth across key therapeutic areas wi
Medicine/Pharmacology - Life Sciences
31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac
Medicine/Pharmacology - Life Sciences
31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.
Medicine/Pharmacology - Life Sciences
30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.
Physics/Materials Science - Microtechnics/Electroengineering
30.05.2017
New Method of Characterizing Graphene
New Method of Characterizing Graphene
Scientists have developed a new method of characterizing graphene‚?‘s properties without applying disruptive electrical contacts, allowing them to investigate both the resistance and quantum capacitance of graphene and other two-dimensional materials. Researchers from the Swiss Nanoscience Institute and the University of Basel‚''s Department of Physics reported their findings in the journal Physical Review Applied.
Physics/Materials Science - Business/Economics
29.05.2017
To the limits of the feasible
First, the engineers and the physicists had to find each other. Then, however, the company Daetwyler built the undulators for the free-electron X-ray laser SwissFEL of the Paul Scherrer Institute PSI as precisely as was possible: to one-tenth of the width of a hair.
Careers/Employment - Environment/Sustainable Development
26.05.2017
Managing an eco-friendly house with Lego-like technology bricks
Managing an eco-friendly house with Lego-like technology bricks
Thanks to startup ThinkEE's modular system - which consists of technology bricks linking various connected devices - data from a host of sensors can be collected regardless of the sensors' protocols.
Environment/Sustainable Development - Business/Economics
26.05.2017
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation Bern, 26.05.2017 - Natural disasters and climate-related risks threaten to reverse hard-won gains in development.
Medicine/Pharmacology - Life Sciences
26.05.2017
Designer Viruses Stimulate the Immune System to Fight Cancer
Swiss scientists have created artificial viruses that can be used to target cancer. These designer viruses alert the immune system and cause it to send killer cells to help fight the tumor. The results, published Communications, provide a basis for innovative cancer treatments. Most cancer cells only provoke a limited reaction from the immune system - the body's defense mechanism - and can thus grow without appreciable resistance.
Medicine/Pharmacology - Life Sciences
26.05.2017
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy † The overall intracranial response r

 
 
Jobs on